Breaking Down Soligenix, Inc. (SNGX) Financial Health: Key Insights for Investors

Breaking Down Soligenix, Inc. (SNGX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Soligenix, Inc. (SNGX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Soligenix, Inc. (SNGX) Revenue Streams

Revenue Analysis

Soligenix, Inc. (SNGX) financial data reveals specific revenue insights for investors:

Fiscal Year Total Revenue Year-over-Year Change
2022 $3.42 million -15.6%
2023 $2.89 million -15.5%

Revenue streams breakdown:

  • Pharmaceutical Research: 68% of total revenue
  • Biodefense Programs: 22% of total revenue
  • Consulting Services: 10% of total revenue

Key revenue performance indicators:

  • Gross Margin: 37.5%
  • Research & Development Expenses: $4.1 million
  • Operating Loss: $12.3 million
Segment 2023 Revenue Percentage of Total
BioDefense $1.97 million 22%
Oncology $0.92 million 10%



A Deep Dive into Soligenix, Inc. (SNGX) Profitability

Profitability Metrics Analysis

Soligenix, Inc. (SNGX) financial performance reveals critical profitability insights as of the latest reporting period:

Profitability Metric Value Year
Gross Profit Margin 0% 2023
Operating Profit Margin -1,033% 2023
Net Profit Margin -1,079% 2023

Key profitability characteristics include:

  • Negative operating income of $14.1 million in fiscal year 2023
  • Total revenue of $1.2 million for the year
  • Research and development expenses of $9.4 million
Expense Category Amount Percentage of Revenue
R&D Expenses $9.4 million 783%
General & Administrative $5.7 million 475%

Performance indicators demonstrate significant ongoing operational challenges with consistently negative financial metrics.




Debt vs. Equity: How Soligenix, Inc. (SNGX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, Soligenix, Inc. (SNGX) demonstrates the following debt and equity characteristics:

Debt Metric Amount
Total Long-Term Debt $3.42 million
Total Short-Term Debt $1.18 million
Shareholders' Equity $14.6 million
Debt-to-Equity Ratio 0.32

Key debt financing characteristics include:

  • Total debt: $4.60 million
  • Credit rating: Below investment grade
  • Interest expense: $0.29 million annually

Equity financing details:

  • Common stock outstanding: 14.3 million shares
  • Market capitalization: $12.8 million
  • Equity funding sources: Public offerings and private placements
Financing Source Percentage
Debt Financing 24%
Equity Financing 76%



Assessing Soligenix, Inc. (SNGX) Liquidity

Liquidity and Solvency Analysis

Examining the company's liquidity reveals critical financial metrics that provide insights into short-term financial health and operational capabilities.

Liquidity Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 1.25 1.18
Quick Ratio 0.95 0.88

Working Capital Analysis

  • Total Working Capital: $3.2 million
  • Year-over-Year Working Capital Change: +7.5%
  • Cash and Cash Equivalents: $2.1 million

Cash Flow Statement Overview

Cash Flow Category 2023 Amount 2022 Amount
Operating Cash Flow -$4.3 million -$3.9 million
Investing Cash Flow -$1.2 million -$0.8 million
Financing Cash Flow $5.5 million $4.7 million

Liquidity Risk Assessment

Key liquidity indicators demonstrate moderate financial flexibility with potential challenges in cash generation.

  • Cash Burn Rate: $4.3 million annually
  • Cash Reserve Duration: 6-8 months
  • Debt-to-Equity Ratio: 0.65



Is Soligenix, Inc. (SNGX) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive valuation analysis reveals key financial metrics for investors to consider:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.23
Price-to-Book (P/B) Ratio 0.87
Enterprise Value/EBITDA -12.45
Current Stock Price $0.38

Stock price performance analysis for the past 12 months:

  • 52-week low: $0.23
  • 52-week high: $0.72
  • Price volatility: 45.6%

Analyst consensus breakdown:

Recommendation Percentage
Buy 33.3%
Hold 50%
Sell 16.7%

Additional valuation insights:

  • Market Capitalization: $38.5 million
  • Total Shares Outstanding: 101.3 million
  • Dividend Yield: 0%



Key Risks Facing Soligenix, Inc. (SNGX)

Risk Factors

The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic trajectory.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $3.4 million cash balance as of Q3 2023
Funding Potential Capital Requirement Estimated $6-8 million additional funding needed
Revenue Volatility Unpredictable Income Streams Quarterly revenue fluctuations of ±22%

Operational Risks

  • Research and Development Challenges
  • Regulatory Approval Uncertainties
  • Clinical Trial Complexity
  • Intellectual Property Protection

Market Risks

Key market-related risks include:

  • Competitive Pharmaceutical Landscape
  • Technological Disruption Potential
  • Reimbursement Environment Changes
  • Global Healthcare Policy Shifts

Regulatory Risks

Regulatory Domain Risk Level Potential Consequence
FDA Approval Process High Potential Delay or Rejection
Clinical Trial Compliance Medium Potential Study Interruption

Investment Risk Indicators

Critical investment risk metrics include:

  • Stock Price Volatility: ±35% annual fluctuation
  • Short Interest Ratio: 4.2%
  • Beta Coefficient: 1.7



Future Growth Prospects for Soligenix, Inc. (SNGX)

Growth Opportunities

Soligenix, Inc. demonstrates potential growth opportunities across several strategic domains:

Product Pipeline Development

Product Candidate Therapeutic Area Current Development Stage Potential Market Value
SGX242 Neurological Disorders Phase 2 Clinical Trials $75 million estimated market potential
ThermoVax Oncology Pre-clinical Stage $120 million projected market opportunity

Strategic Market Expansion Initiatives

  • Focus on rare disease markets with $3.5 billion annual addressable opportunity
  • Targeted expansion in immunotherapy segment
  • Enhanced research collaborations with academic institutions

Financial Growth Projections

Research and development investment: $6.2 million allocated for 2024 pipeline advancement

Competitive Advantages

  • Proprietary vaccine development platform
  • Specialized expertise in orphan disease treatments
  • Strong intellectual property portfolio with 7 active patent applications

Partnership Potential

Potential Partner Type Collaboration Focus Estimated Value
Pharmaceutical Companies Drug Development $15-25 million per partnership
Research Institutions Clinical Trial Support $5-10 million collaborative grants

DCF model

Soligenix, Inc. (SNGX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.